Company: GHRS
Filing Date: 2025-07-29
Form Type: 20-F/A
Source: 0001140361-25-027850
Chunk: 269

Company: GH Research PLC
Filing Date: 2025-07-29
Form: 20-F/A
Chunk 269
---
 market funds and marketable securities and the measurement of share-based payments at initial date of award. The financial information presented in this report does not represent full statutory accounts as defined by the Companies Act 2014. The statutory accounts of GH Research PLC for the year ended December 31, 2024, are expected to be filed with the Companies Registration Office by November 26, 2025. New and amended IFRS Accounting Standards There are no new IFRS Accounting Standards, amendments to standards or interpretations that are mandatory for the financial year beginning on January 1, 2024, that are relevant to the Group and that have had any material impact on the consolidated financial statements. The review of the impact of new standards on the Group’s financial statements which are not yet effective and which have not been early adopted by the Group is ongoing. This includes the recently issued IFRS 18 “Presentation and Disclosure in Financial Statements”. Going concern basis GH Research is a clinical-stage biopharmaceutical company developing innovative therapeutics. The Group is exposed to all risks inherent in establishing and developing its business, including the substantial uncertainty that current projects will succeed. Research and development expenses have been incurred from the start of the Group’s activities, generating negative cash flows from operating activities since formation. Since its incorporation, the Group has funded its growth through capital increases. The Group has nobank loans or other debt outstanding, except lease liabilities, as of December 31, 2024. As a result, the Group is not exposed to liquidity risk through requests for early repayment of loans. As of December 31, 2024, the Group’s cash and cash equivalents amounted to $ 100.8million (December 31, 2023: $ 78.4million). The Group also held marketable securities of $ 62.4million and other financial assets of $ 19.4million as of December 31, 2024 (December 31, 2023: marketable securities of $ 88.7million and other financial assets of $ 55.6 million). The Group’s marketable securities are quoted in active markets and are an additional source of liquidity. The Board of Directors believes that the Group has sufficient financial resources available to cover its planned cash outflows for at least the next twelve months from the date of issuance of these consolidated financial statements. The Group, therefore, continues to adopt the going concern basis in preparing its consolidated financial statements. Use of estimates and judgments The preparation of the consolidated financial statements